Executives from AstraZeneca PLC and Bristol-Myers Squibb Company have met in recent months to explore the possibility of merging the two pharmaceutical groups into a single company with a combined market value approaching $400 billion, according to people briefed on the discussions.
Those conversations, while real, are described as preliminary. The individuals cited caution that negotiations could stall or collapse, and neither company has offered any comment or provided a statement. No details have been disclosed about any potential transaction mechanics or whether the talks are continuing.
Deal scale and market positioning
A combination of the two firms would place the merged company among the world’s largest drugmakers. AstraZeneca currently carries a market capitalisation of roughly $264 billion, while Bristol Myers Squibb contributes about $133 billion toward the combined valuation presented in reports.
That scale underscores why a deal would attract close attention from investors and regulators. The size of a cross-border transaction of this magnitude would likely invite scrutiny from multiple competition authorities, including the U.S. Federal Trade Commission, the UK Competition and Markets Authority and the European Commission.
Share performance and recent operating results
Market moves in recent sessions reflect differing momentum for the two names. AstraZeneca’s NYSE-listed shares closed Friday at $169.64, down $1.70 on the day, and sit more than $40 below their 52-week high of $212.71. Bristol Myers Squibb closed Friday at $65.31, near its intraday 52-week high of $65.66, on above-average volume of 14.58 million shares.
Bristol Myers Squibb has recorded meaningful appreciation over the last year, gaining roughly 47.7 percent. That rally has been supported by strong second-quarter results: Q2 2026 GAAP EPS of $2.04 beat consensus of $1.61, and revenue of $12.97 billion topped estimates of $11.71 billion.
AstraZeneca also delivered a solid Q2 showing, reporting EPS of $2.63 against an estimate of $2.48 and revenue of $15.38 billion versus a consensus of $15.45 billion on July 27.
Strategic context and recent company actions
Under its current chief executive, AstraZeneca has previously rebuffed a takeover approach and has pursued moves to strengthen its U.S. presence. The company rejected a $118 billion approach from Pfizer in 2014, and its share price has risen substantially since that episode. AstraZeneca has also announced a $50 billion U.S. manufacturing and research and development investment commitment and publicised plans for a direct U.S. listing aimed at capturing stronger American equity valuations. How a potential combination with Bristol Myers Squibb would align with those strategic priorities has not been disclosed and would need to be addressed by management.
Bristol Myers Squibb has used acquisitions to bolster a pipeline under pressure from patent expiries, with GAAP R&D spending falling roughly 11 percent to about $10 billion in 2025. The company’s oncology and immunology assets, supported by partnership agreements with BioNTech and Hengrui Pharma, have been cited as contributors to recent stock strength. Observers say that a larger platform could help accelerate diversification of the pipeline, though no transaction specifics have been made public.
Regulatory and timing considerations
A cross-border merger of this scale would face multi-jurisdictional regulatory reviews that are likely to be complex and time-consuming. The simultaneous involvement of the FTC, the UK Competition and Markets Authority and the European Commission would present a significant layer of oversight that could influence deal structure, timing and remedies.
Investors will have scheduled opportunities to assess each company’s near-term performance: Bristol Myers Squibb is due to report Q3 2026 results on October 29, where consensus forecasts EPS of $1.61 on revenue of $12.04 billion. AstraZeneca is slated to report on October 30, with consensus EPS of $2.63 on revenue of $16.06 billion. Any announcement made before those reporting dates could pre-empt or materially change guidance discussions on the respective earnings calls.
Monday’s market open after the report about the talks will provide the earliest clear signal of how investors are pricing the likelihood of a transaction.
What remains unclear
Beyond the broad facts that talks have occurred and that any combination would be large, important details are missing. There is no disclosed deal structure, no confirmed timetable and no comment from either company. The discussions were described as taking place over recent months, but participants warned they could be delayed or abandoned altogether.
Given those limitations, market participants will be watching regulatory signals, upcoming quarterly results and any corporate disclosures for additional clarity.